AstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling both companies ...
An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...
More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...
On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...
Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...
Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results